Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YGY
|
|||
| Former ID |
DIB005374
|
|||
| Drug Name |
MK-6302
|
|||
| Synonyms |
INS-20; Pegylated GCSF, Insmed/Merck
Click to Show/Hide
|
|||
| Indication | Neutropenia [ICD-11: 4B00.0; ICD-9: 288] | Phase 1 | [1] | |
| Company |
Insmed Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor receptor (G-CSF-R) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Merck. | |||
| REF 2 | Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.